SCHEMBL6918970

SCHEMBL6918970

O=C(NO)c1ccc(=O)[nH]c1

nearest known ligand 0.62

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 1/20 0.53
EPHX2 P34913 3/20 0.50
KMT2A Q03164 2/20 0.50
MEN1 O00255 1/20 0.50
RAB9A P51151 2/20 0.49
MAPT P10636 1/20 0.48
HDAC6 Q9UBN7 2/20 0.47
HDAC1 Q13547 1/20 0.47
HDAC2 Q92769 1/20 0.47
HDAC8 Q9BY41 1/20 0.47
LMNA P02545 1/20 0.47
GAA P10253 1/20 0.47
SMN1; SMN2 Q16637 1/20 0.47
APOBEC3A P31941 1/20 0.46
APOBEC3G Q9HC16 1/20 0.46
APOBEC3B Q9UH17 1/20 0.46
POLB P06746 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28192657 0.82 L3MBTL1 (0.55) L3MBTL1EPHX2KMT2AMEN1RAB9A
SCHEMBL447082 0.82 L3MBTL1 (0.51) L3MBTL1EPHX2KMT2AMEN1RAB9A
SCHEMBL12376722 0.77 SMN1; SMN2 (0.59) L3MBTL1EPHX2KMT2AMEN1RAB9A
SCHEMBL12561259 0.77 L3MBTL1 (0.59) L3MBTL1EPHX2KMT2AMEN1RAB9A
SCHEMBL13701751 0.77 KMT2A (0.48) L3MBTL1EPHX2KMT2AMEN1RAB9A
Hydrochloric Acid SCHEMBL30612668 0.77 L3MBTL1 (0.46) L3MBTL1EPHX2KMT2AMEN1RAB9A
SCHEMBL3370719 0.76 POLB (0.59) L3MBTL1EPHX2KMT2AMEN1RAB9A
SCHEMBL657937 0.74 POLB (0.47) L3MBTL1EPHX2KMT2AMEN1RAB9A
SCHEMBL2366245 0.74 POLB (0.44) L3MBTL1EPHX2KMT2AMEN1RAB9A
SCHEMBL4004484 0.74 KMT2A (0.45) L3MBTL1EPHX2KMT2AMEN1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2004022536-A1 NEW HETEROCYCLIC AMIDE COMPOUNDS USEFUL FOR THE TREATMENT OF INFLAMMATORY AND ALLERGIC DISORDERS: PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM GLENMARK PHARMACEUTICALS LIMITED (US) 2004-03-18 WO disclosed